Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

Executive Summary

The reform 'blueprint' might actually live up to its hype.

You may also be interested in...



Beyond The "Blueprint": The Next Stage For US HHS Drug Price Policy

Upcoming transition in HHS drug pricing policy staff reinforces the Trump Administration's shift away from the 2018 "Blueprint” and towards engaging with bipartisan Congressional legislation – and spotlighting executive action as coming from the White House in the context of the upcoming Presidential campaign.

Turning Question Marks Into Check Marks: HHS Blueprint One Year Later

Direct-to-consumer ad rule is first of a series of high-profile regulations aimed at lowering drug prices and reducing out-of-pocket costs that the Trump Administration hopes to implement by 2020.

Medicare Part D Payment Model Gives Health Plans More Incentives To Negotiate Lower Drug Prices

Participating plans to share in savings if they stay below spending target for Part D catastrophic phase and repay 10% of any excess spending; CMS also updates its VBID model.

Related Content

Topics

UsernamePublicRestriction

Register

PS123094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel